OM
TBPH icon

Opaleye Management’s Theravance Biopharma TBPH Stock Holding History

Opaleye Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-543,500
Closed -$5.63M – 52
2023
Q2 		$5.63M Sell
543,500
-2,804
-0.5% -$31K 1.35% 20
2023
Q1 		$5.93M Buy
546,304
+458,704
+524% +$4.85M 1.78% 16
2022
Q4 		$983K Buy
+87,600
New +$921K 0.34% 38
2017
Q4 		– Sell
-180,000
Closed -$6.16M – 41
2017
Q3 		$6.16M Hold
180,000
– – 2.18% 17
2017
Q2 		$7.17M Hold
180,000
– – 3% 9
2017
Q1 		$6.63M Buy
180,000
+21,800
+14% +$696K 3.3% 8
2016
Q4 		$5.04M Buy
+158,200
New +$4.91M 2.97% 11

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opaleye Management's TBPH Position: Q3 2023 in Review

Opaleye Management sold out of Theravance Biopharma (TBPH) in Q3 2023, closing a stake of 543,500 shares — an estimated $5.63M sold.

Opaleye Management first reported a position in TBPH in Q4 2016 and held it in 7 quarters. The position peaked at $7.17M in Q2 2017. 115 funds tracked by Wall St. Rank hold TBPH as of Q3 2023.

  • Opaleye Management reported no remaining Theravance Biopharma position as of Q3 2023 after selling out during the quarter.
  • Opaleye Management sold 543,500 Theravance Biopharma shares in Q3 2023, an estimated $5.63M.
  • Opaleye Management first reported a position in Theravance Biopharma in Q4 2016 and held it in 7 quarters.
  • Opaleye Management's Theravance Biopharma position peaked at $7.17M in Q2 2017.
  • 115 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.